• ChemFaces is a professional high-purity natural products manufacturer.
  • Product Intended Use
  • 1. Reference standards
  • 2. Pharmacological research
  • 3. Inhibitors
  • Home
  • Biologically Active
  • Hot Products
  • Plant Catalog
  • Products
  • Customer Support
  • Product Use Citation
  • About Us
  • Contact Us
  • Formononetin

    Catalog No. CFN99962
    CAS No. 485-72-3
    Molecular Weight: 268.27
    Molecular Formula C16H12O4
    DBs [PubChem]:4115
    [ChEMBL]:18088
    [PCIDB]:2525

    Standard InChI:

    InChI=1S/C16H12O4/c1-19-12-5-2-10(3-6-12)14-9-20-15-8-11(17)4-7-13(15)16(14)18/h2-9,17H,1H3

    Biological Activity

    Formononetin causes vascular relaxation via endothelium/NO-dependent mechanism and endothelium-independent mechanism which involves the activation of BK(Ca) and K(ATP) channels.[1]
    Formononetin-treated Ovx rats has an increased bone osteoprotegerin-to-receptor activator for nuclear κB ligand ratio compared with the Ovx + vehicle group; daily oral administration of formononetin for 12 weeks has a substantial anabolic effect, thus raising the possibility of its use in postmenopausal osteoporosis.[2]
    Formononetin exhibits antiviral activities against some members of Picornaviridae, could inhibit EV71-induced COX-2 expression and PGE2 production via MAPKs pathway including ERK, p38 and JNK, thus, formononetin could be a potential lead or supplement for the development of new anti-EV71 agents in the future.[3]
    Formononetin reduces hydrogen peroxide (H2O2)-induced apoptosis and improves the levels or activity of indicators of oxidative stress, also inhibits the activation of nuclear factor-kappaB (NF-κB), which is a significant transcription factor for RGC-5 apoptosis.[4]

    Product

    Official website: Formononetin
    Japanese website: Formononetin
    Chinese website: Formononetin

    References

    [1] Wu J H, Li Q, Wu M Y, et al. J Nutr Biochem, 2010, 21(7):613-20.
    [2]Tyagi A M, Srivastava K, Singh A K, et al. Menopause, 2012, 19(8):856-63.
    [3] Wang H, Zhang D, Miao G, et al. Viro J, 2015, 12(1):1-10.
    [4] Jia W C, Liu G, Zhang C D, et al. Eur Rev Med & Pharmaco, 2014, 18(15):2191-7.
    [5] Xing J H, Sun X L, Zhou J.Chinese Journal of Pharmaceutical Analysis, 2009(01):73-5.

    Product Use Citation